An open-label, uncontrolled, multi-center phase II study to investigate efficacy, safety and pharmacokinetic of ONO-4538 in relapsed/refractory Hodgkin Lymphoma patients
Latest Information Update: 07 Dec 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 22 Oct 2020 Results published in the Japanese Journal of Clinical Oncology
- 13 Jun 2016 New trial record
- 07 Jun 2016 Interim nalysis presented at the 52nd Annual Meeting of the American Society of Clinical Oncology